

23 July 2026

Endometrial Cancer Treatments

1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli) <5
- Dostarlimab (Jemperli) + Chemotherapy 7
- Hormone therapy (Progesterone or Letrozole) 0
- Lenvatinib + Pembrolizumab (Keytruda + Lenvima) 0
- Pembrolizumab monotherapy (Keytruda) <5
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 27
- Durvalumab with Platinum-based Chemotherapy 0
- Pembrolizumab with Platinum-based Chemotherapy <5
- Any other SACT Paclitaxel <5, Weekly Carboplatin+XRT <5
- If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy 0

2. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) + Chemotherapy <5
- Hormone therapy (Progesterone or Letrozole) 0
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 21
- Durvalumab with Platinum-based Chemotherapy 0
- Pembrolizumab with Platinum-based Chemotherapy <5
- Any other SACT Weekly Carboplatin+XRT <5
- If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for first line Endometrial cancer 0

3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

There are currently no clinical trials open in endometrial cancer in Belfast Trust.

23 July 2026

* Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.